This IP strength and advancing clinical trials (bioequivalence) set the stage for a strong upward trend in the stock price as commercialization paths solidify. #BioNxt #BiotechIP #StockWatch
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.